Interacting drugs |
Interacting active principles |
Interaction severity |
Interaction
effects |
COVID-19 medication with other COVID-19 therapies |
HCQ-azithromycin |
Moderate |
Increased risk of QT ECG
prolongation. |
|
HCQ-lopinavir/ritonavir |
Major |
Increased risk of QT ECG
prolongation. |
|
HCQ-tocilizumab |
Moderate |
Increased risk of peripheral
neuropathy. |
|
Lopinavir/ritonavir-azithromycin |
Moderate |
Increased risk of QT ECG
prolongation. |
|
Lopinavir/ritonavir-darunavir/cobicistat |
Moderate |
Altered blood
levels and effects of both medications due to darunavir/cobicistat
inhibition and lopinavir inhibition or induction of CYP450
3A4. |
COVID-19 medication with CNS medications |
Azithromycin-citalopram |
Major |
Increased risk of QT ECG
prolongation. |
|
Azithromycin-haloperidol |
Major |
Increased risk of QT ECG
prolongation. |
|
Azithromycin-olanzapine |
Moderate |
Increased risk of QT ECG
prolongation. |
|
Azithromycin-promazine |
Moderate |
Increased risk of QT ECG
prolongation. |
|
Azithromycin-quetiapine |
Moderate |
Increased risk of QT ECG
prolongation. |
|
Azithromycin-trazodone |
Moderate |
Increased risk of QT ECG
prolongation. |
|
Darunavir/cobicistat-alprazolam |
Moderate |
Increased blood levels of
alprazolam due to darunavir/cobicistat inhibition of CYP450
3A4. |
|
Darunavir/cobicistat-clonazepam |
Moderate |
Increased blood levels of
clonazepam due to darunavir/cobicistat inhibition of CYP450
3A4. |
|
Darunavir/cobicistat-midazolam |
Major |
Increased blood levels of
midazolam due to darunavir/cobicistat inhibition of CYP450
3A4. |
|
Darunavir/cobicistat-risperidone |
Moderate |
Increased blood levels
of risperidone to darunavir/cobicistat inhibition of CYP450
3A4. |
|
Darunavir/cobicistat-sertraline |
Moderate |
Decreased blood levels
and effects of sertraline. |
|
Enoxaparin-citalopram |
Moderate |
Increased risk of
bleeding. |
|
Enoxaparin-sertraline |
Moderate |
Increased risk of
bleeding. |
|
HCQ-citalopram |
Major |
Increased risk of QT ECG
prolongation. |
|
HCQ-codeine |
Moderate |
Increased risk of codeine reduced
efficacy. |
|
HCQ-haloperidol |
Major |
Increased risk of QT ECG
prolongation. |
|
HCQ-olanzapine |
Moderate |
Increased risk of QT ECG
prolongation. |
|
HCQ-promazine |
Major |
Increased risk of QT ECG
prolongation. |
|
HCQ-quetiapine |
Major |
Increased risk of QT ECG
prolongation. |
|
HCQ-risperidone |
Moderate |
Increased risk of QT ECG
prolongation. |
|
HCQ-sertraline |
Moderate |
Increased risk of QT ECG
prolongation. |
|
HCQ-trazodone |
Major |
Increased risk of QT ECG
prolongation. |
|
Lopinavir/ritonavir-citalopram |
Major |
Increased risk of QT ECG
prolongation. |
|
Lopinavir/ritonavir-haloperidol |
Major |
Increased risk of QT ECG
prolongation and increased blood levels of haloperidol due to
lopinavir/ritonavir inhibition of CYP450 2D6. |
|
Lopinavir/ritonavir-olanzapine |
Moderate |
Increased risk of QT ECG
prolongation. |
|
Lopinavir/ritonavir-promazine |
Moderate |
Increased risk of QT ECG
prolongation. |
|
Lopinavir/ritonavir-quetiapine |
Major |
Increased blood levels of
quetiapine due to lopinavir/ritonavir inhibition of CYP450 3A4 and
increased risk of QT ECG prolongation. |
|
Lopinavir/ritonavir-risperidone |
Moderate |
Increased risk of QT ECG
prolongation. |
|
Lopinavir/ritonavir-sertraline |
Moderate |
Increased risk of QT ECG
prolongation. |
|
Lopinavir/ritonavir-valproic acid |
Moderate |
Reduced blood levels of
valproate due to lopinavir/ritonavir induction of
glucuronosyltransferases. |
|
Tocilizumab-amlodipine |
Moderate |
Decreased blood levels of
amlodipine. |
|
Tocilizumab-clonazepam |
Moderate |
Decreased blood levels of
clonazepam. |
|
Tocilizumab-midazolam |
Moderate |
Decreased blood levels of
midazolam. |
COVID-19 medication with CV medications |
Azithromycin-atorvastatin or simvastatin |
Moderate |
Increased blood
levels of atorvastatin and increased risk of liver damage and myopathy
due to azithromycin inhibition of CYP450 3A4. |
|
Azithromycin-sertraline |
Moderate |
Increased risk of QT ECG
prolongation. |
|
Azithromycin-warfarin |
Moderate |
Increased risk of
bleeding. |
|
Darunavir/cobicistat-amiodarone |
Major |
Increased risk of QT ECG
prolongation due to darunavir/cobicistat inhibition of CYP450
3A4. |
|
Darunavir/cobicistat-amlodipine |
Moderate |
Increased blood levels of
amlodipine due to darunavir/cobicistat inhibition of CYP450
3A4. |
|
Darunavir/cobicistat-apixaban |
Major |
Increased blood levels of
apixaban and increased risk of bleeding due to darunavir/cobicistat
inhibition of CYP450 3A4 and P-glycoprotein. |
|
Darunavir/cobicistat-atorvastatin or simvastatin |
Major |
Increased
blood levels of atorvastatin and increased risk of liver damage and
myopathy due to darunavir/cobicistat inhibition of CYP450
3A4. |
|
Darunavir/cobicistat-nebivolol |
Moderate |
Increased blood levels of
bisoprolol due to darunavir/cobicistat inhibition of CYP450
3A4. |
|
Darunavir/cobicistat-rivaroxaban |
Major |
Increased blood levels of
rivaroxaban and increased risk of bleeding due to darunavir/cobicistat
inhibition of CYP450 3A4. |
|
Darunavir/cobicistat-warfarin |
Moderate |
Altered blood levels of
warfarin. |
|
Enoxaparin-amiodarone |
Major |
Increased risk of
bleeding. |
|
Enoxaparin-apixaban |
Major |
Increased risk of
bleeding. |
|
Enoxaparin-clopidogrel |
Major |
Increased risk of
bleeding. |
|
Enoxaparin-losartan or valsartan |
Moderate |
Increased risk of
hyperkalaemia. |
|
Enoxaparin-perindopril |
Moderate |
Increased risk of
hyperkalaemia. |
|
Enoxaparin-warfarin |
Major |
Increased risk of
bleeding. |
|
HCQ-amiodarone |
Major |
Increased risk of QT ECG
prolongation. |
|
HCQ-atorvastatin or simvastatin |
Moderate |
Increased risk of
peripheral neuropathy. |
|
Lopinavir/ritonavir-apixaban |
Major |
Increased blood levels of
apixaban and increased risk of bleeding due to ritonavir
lopinavir/inhibition of CYP450 3A4 and P-glycoprotein. |
|
Lopinavir/ritonavir-atorvastatin or simvastatin |
Major |
Increased
blood levels of atorvastatin and increased risk of liver damage and
myopathy due to lopinavir/ritonavir inhibition of CYP450
3A4. |
|
Lopinavir/ritonavir-bisoprolol |
Moderate |
Increased risk of PR ECG
prolongation. |
|
Lopinavir/ritonavir-verapamil |
Moderate |
Increased risk of
hypotension and of PR ECG prolongation. |
|
Tocilizumab-atorvastatin |
Moderate |
Decreased levels of
atorvastatin. |
COVID-19 medication with other medications |
Azithromycin-loperamide |
Moderate |
Increased risk of QT ECG
prolongation. |
|
Darunavir/cobicistat-betamethasone |
Moderate |
Increased blood levels
of betamethasone due to darunavir/cobicistat inhibition of CYP450
3A4. |
|
Darunavir/cobicistat-clopidogrel |
Major |
Decreased efficacy of
clopidogrel due to darunavir/cobicistat inhibition of CYP450 3A4/5, 1A2,
2B6. |
|
Darunavir/cobicistat-dutasteride |
Moderate |
Increased blood levels
of dutasteride. |
|
Darunavir/cobicistat-ruxolitinib |
Major |
Increased blood levels of
ruxolitinib due to darunavir/cobicistat inhibition of CYP450
3A4. |
|
HCQ-bicalutamide |
Moderate |
Increased risk of QT ECG
prolongation. |
|
HCQ-fluticasone propionate/vilanterol |
Moderate |
Increased risk of
QT ECG prolongation. |
|
HCQ-gliclazide |
Moderate |
Increased risk of
hypoglycaemia. |
|
HCQ-linezolid |
Moderate |
Increased risk of
neuropathy. |
|
HCQ-loperamide |
Moderate |
Increased risk of QT ECG
prolongation. |
|
Lopinavir/ritonavir-betamethasone |
Moderate |
Increased blood levels
of betamethasone due to lopinavir/ritonavir inhibition of CYP450
3A4. |
|
Lopinavir/ritonavir-clopidogrel |
Major |
Decreased efficacy of
clopidogrel due to lopinavir/ritonavir inhibition of CYP450 3A4/5, 1A2,
2B6. |
|
Lopinavir/ritonavir-dutasteride |
Moderate |
Increased blood levels of
dutasteride due to lopinavir/ritonavir inhibition of CYP450
3A4. |
|
Lopinavir/ritonavir-fluticasone propionate/vilanterol |
Major |
Increased exposure to fluticasone propionate and vilanterol due to
lopinavir/ritonavir inhibition of CYP450 3A4 and increased risk of QT
ECG prolongation. |
|
Lopinavir/ritonavir-gliclazide |
Moderate |
Increased risk of
hyperglycaemia. |
|
Lopinavir/ritonavir-insulin |
Moderate |
Increased risk of insulin
inefficacy. |
|
Lopinavir/ritonavir-levothyroxine |
Moderate |
Reduced blood levels of
thyroxine due to lopinavir/ritonavir induction of
glucuronosyltransferase. |
|
Lopinavir/ritonavir-metformin |
Moderate |
Increased risk of
hyperglycaemia. |
|
Lopinavir/ritonavir-methylprednisolone |
Major |
Increased blood
levels of methylprednisolone due to lopinavir/ritonavir inhibition of
CYP450 3A4. |
|
Lopinavir/ritonavir-tamsulosin |
Major |
Increased blood levels of
tamsulosin due to lopinavir/ritonavir inhibition of CYP450 3A4 and 2D6;
increased risk of hypotension and priapism. |
|
Lopinavir/ritonavir-vildagliptin |
Moderate |
Increased risk of
hyperglycaemia. |